|
1
|
Glynne-Jones R, Wyrwicz L, Tiret E, Brown
G, Rödel C, Cervantes A and Arnold D: ESMO Guidelines Committee:
Rectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv22–iv40.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, et al: Preoperative radiotherapy with or without
concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bosset JF, Collette L, Calais G, Mineur L,
Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier
JC: EORTC Radiotherapy Group Trial 22921: Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med.
355:1114–1123. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Greenhalgh TA, Dearman C and Sharma RA:
Combination of novel agents with radiotherapy to treat rectal
cancer. Clin Oncol (R Coll Radiol). 28:116–139. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shirasaka T, Nakano K, Takechi T, Satake
H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, et al:
Antitumor activity of 1 M tegafur-0.4 M
5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against
human colon carcinoma orthotopically implanted into nude rats.
Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
|
|
7
|
Zeng L, Ou G, Itasaka S, Harada H, Xie X,
Shibuya K, Kizaka-Kondoh S, Morinibu A, Shinomiya K and Hiraoka M:
TS-1 enhances the effect of radiotherapy by suppressing
radiation-induced hypoxia-inducible factor-1 activation and
inducing endothelial cell apoptosis. Cancer Sci. 99:2327–2335.
2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takagi M, Sakata K, Someya M, Tauchi H,
Iijima K, Matsumoto Y, Torigoe T, Takahashi A, Hareyama M and
Fukushima M: Gimeracil sensitizes cells to radiation via inhibition
of homologous recombination. Radiother Oncol. 96:259–266.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sakata K, Someya M, Matsumoto Y, Tauchi H,
Kai M, Toyota M, Takagi M, Hareyama M and Fukushima M: Gimeracil,
an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early
step in homologous recombination. Cancer Sci. 102:1712–1716.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Kamijo A, Murayama C, Akiba T and Nakayama Y: Phase I/II study of
preoperative concurrent chemoradiotherapy with S-1 for locally
advanced, resectable rectal adenocarcinoma. Oncology. 81:306–311.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Inomata M, Akagi T, Nakajima K, Etoh T,
Tahara K, Matsumoto T, Ogawa T, Fujii K, Shiromizu A and Kitano S:
A prospective feasibility study to evaluate neoadjuvant-synchronous
S-1 with radiotherapy for locally advanced rectal cancer: A
multicentre phase II trial. Mol Clin Oncol. 4:510–514.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hiratsuka T, Etoh T, Hara T, Akagi T,
Tahara K, Matsumoto T, Ogawa T, Fujii K, Shiromizu A, Shiroshita H
and Inomata M: Long-term outcomes of neoadjuvant-synchronous S-1
plus radiotherapy for locally advanced rectal cancer: A
multi-institutional prospective phase II study. J Anus Rectum
Colon. 2:168–175. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hofheinz RD, Wenz F, Post S, Matzdorff A,
Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et
al: Chemoradiotherapy with capecitabine versus fluorouracil for
locally advanced rectal cancer: A randomised, multicentre,
non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588.
2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lawrence TS, Blackstock AW and McGinn C:
The mechanism of action of radiosensitization of conventional
chemotherapeutic agents. Semin Radiat Oncol. 13:13–21.
2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hamaguchi T, Shimada Y, Mizusawa J,
Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T,
Takii Y, et al: Capecitabine versus S-1 as adjuvant chemotherapy
for patients with stage III colorectal cancer (JCOG0910): An
open-label, non-inferiority, randomised, phase 3, multicentre
trial. Lancet Gastroenterol Hepatol. 3:47–56. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kim JS, Kim JS, Cho MJ, Song KS and Yoon
WH: Preoperative chemoradiation using oral capecitabine in locally
advanced rectal cancer. Int J Radiat Oncol Biol Phys. 54:403–408.
2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kim JC, Kim TW, Kim JH, Yu CS, Kim HC,
Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, et al: Preoperative
concurrent radiotherapy with capecitabine before total mesorectal
excision in locally advanced rectal cancer. Int J Radiat Oncol Biol
Phys. 63:346–353. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Krishnan S, Janjan NA, Skibber JM,
Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM,
Eng C, et al: Phase II study of capecitabine (Xeloda) and
concomitant boost radiotherapy in patients with locally advanced
rectal cancer. Int J Radiat Oncol Biol Phys. 66:762–771.
2006.PubMed/NCBI View Article : Google Scholar
|
